Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 19;33(4):837-849.
doi: 10.32604/or.2024.053882. eCollection 2025.

The regulatory role of lncRNA in tumor drug resistance: refracting light through a narrow aperture

Heng Zhang  1 , Xiao Yang  2 , Yujin Guo  3 , Haibo Zhao  4 , Pei Jiang  5 , Qing-Qing Yu  3
Affiliations
Review

The regulatory role of lncRNA in tumor drug resistance: refracting light through a narrow aperture

Heng Zhang et al. Oncol Res. .

Abstract

As living conditions improve and diagnostic capabilities advance, the incidence of tumors has increased, with cancer becoming a leading cause of death worldwide. Surgery, chemotherapy, and radiotherapy are the most common treatments. Despite advances in treatment options, chemotherapy remains a routine first-line treatment for most tumors. Due to the continuous and extensive use of chemotherapy drugs, tumor resistance often develops, becoming a significant cause of treatment failure and poor prognosis. Recent research has increasingly focused on how long stranded non-coding RNAs (LncRNAs) influence the development of malignant tumors and drug resistance by regulating gene expression and other biological mechanisms during cell growth. Studies have demonstrated that variations in lncRNA expression levels, influenced by both interpatient variability and intratumoral genetic and epigenetic differences, are closely linked to tumor drug resistance. Therefore, this review advocates using lncRNA as a framework to investigate the regulation of genes associated with drug resistance, proposing lncRNA-targeted therapeutic strategies to potentially increase the efficacy of chemotherapy, improve patient outcomes, and guide future research directions.

Keywords: Chemotherapy; Gene regulatory mechanisms; Long chain non coding RNA (LncRNA); Tumor resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest to report regarding the present study.

Figures

Figure 1
Figure 1. The role of lncRNA in tumor drug resistance.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chow Laura QM. Head and neck cancer. N Engl J Med. 2020;382(1):60–72. doi:10.1056/NEJMra1715715; - DOI - PubMed
    1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer cases in 185 countries. CA Cancer J Clin. 2024;74(3):229–63. doi:10.3322/caac.v74.3. - DOI - PubMed
    1. Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C, et al. . Multidrug resistance (MDR): a widespread phenomenon in pharmacological therapies. Molecules. 2022;27(3):616. doi:10.3390/molecules27030616; - DOI - PMC - PubMed
    1. Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C. Surmounting cancer drug resistance: new insights from the perspective of N6 methyladenosine RNA modification. Drug Resist Update. 2020;53:100720. doi:10.1016/j.drup.2020.100720; - DOI - PubMed
    1. Parikh AR, Leshchiner I, Elagina L, Goyal L, Levovitz C, Siravegna G, et al. . Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25(9):1415–21. doi:10.1038/s41591-019-0561-9; - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources